SUPN (Supernus Pharmaceuticals) Shares Outstanding (Basic Average): 57.6 Mil (As of Mar. 2026)


SUPN Supernus Pharmaceuticals Inc SUPN
87 GF Score
Price $45.13
GF Value $40.55
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Shares Outstanding (Basic Average)?

Supernus Pharmaceuticals SUPN +1.53% 87 Shares Outstanding (Basic Average) is 57.6 Mil as of Mar. 2026. GuruFocus rates SUPN with a GF Score™ of 87/100 and a GF Value™ of $40.55 (Modestly Overvalued).

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Supernus Pharmaceuticals's average basic shares outstanding for the quarter that ended in Mar. 2026 was 57.6 Mil.


Supernus Pharmaceuticals  (NAS:SUPN) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Supernus Pharmaceuticals Shares Outstanding (Basic Average) Related Terms


Supernus Pharmaceuticals Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Shares Outstanding (Basic Average) Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.10 53.67 54.54 55.10 56.45

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.87 56.03 56.55 57.40 57.65
SUPN
87GF Score
Supernus Pharmaceuticals Inc SUPN
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 57.6 Mil mean?
Supernus Pharmaceuticals (SUPN) has a Shares Outstanding (Basic Average) of 57.6 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Shares Outstanding (Basic Average) too high?
Supernus Pharmaceuticals' current Shares Outstanding (Basic Average) is 57.6 Mil. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Shares Outstanding (Basic Average) compare to BCRX and PBH?
Supernus Pharmaceuticals' Shares Outstanding (Basic Average) of 57.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Drug Manufacturers company?
A good Shares Outstanding (Basic Average) depends on the Drug Manufacturers industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Shares Outstanding (Basic Average) is 57.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (SUPN) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.55, compared to a current price of $45.13 — trading 11.3% above its estimated fair value. The current Shares Outstanding (Basic Average) is 57.6 Mil. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Supernus Pharmaceuticals (SUPN), the current Shares Outstanding (Basic Average) is 57.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (SUPN) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $45.13 is trading 11.3% above its estimated GF Value™ of $40.55. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for SUPN:

  • Shares Outstanding (Basic Average): 57.6 Mil
  • GF Value™: $40.55 vs. price of $45.13 (11.3% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the SUPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supernus Pharmaceuticals Business Description

Other Exchanges 0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for SUPN

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.13
Price
$40.55
GF Value